Cost-effectiveness of left ventricular assist devices as destination therapy in the United Kingdom.

ABSTRACT:

Aims

Continuous-flow left ventricular assist devices (LVADs) as destination therapy (DT) are a recommended treatment by National Institute for Health and Care Excellence England for end-stage heart failure patients ineligible for cardiac transplantation. Despite the fact that DT is frequently used as an LVAD indication across other major European countries and the United States, with consistent improvements in quality-of-life and longevity, National Health Service (NHS) England does not currently fund DT, mainly due to concerns over cost-effectiveness. On the basis of the recently published ENDURANCE Supplemental Trial studying DT patients, we assessed for the first time the cost-effectiveness of DT LVADs compared with medical management (MM) in the NHS England.

Methods and resu

SUBMITTER: Schueler S 

PROVIDER: S-EPMC8318455 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature